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Abstract
Background: When contracted in pregnancy, rubella may cause serious chronic infection of the fetus and
development of Congenital Rubella Syndrome. Despite widespread application of rubella vaccination, periodical
outbreaks are still being reported worldwide. The aim of this study was to determine rubella seroprevalence and
antibody levels in neonates in Serbia as a proxy of maternal serostatus.
Methods: ELISA based serological testing for rubella was done in 599 neonates treated at the Institute of
Neonatology in Belgrade, from January 2010 to December 2011. All individuals with rubella IgG concentration
≥10 IU/ml were considered seropositive for rubella.
Results: The mean age of enrolled neonates was 18 ± 6 days. The overall seroprevalence of rubella IgG antibodies
among the tested neonates was 540/599(90.2 %, 95 % CI: 87.5–92.3). Seropositivity rate among sera of the neonates
enrolled in 2010 was significantly higher than those collected in 2011 (p < 0.0001). There was no difference in
average maternal age, gestational age or frequency of receiving blood products among the two study years.
Significant high seropositivity rate was observed among neonates from mother aged >30 as compared to those
from mothers aged <20 years (p = 0.02). Significant difference was also found between average IgG titers in the two
study years (79 IU/mL in 2010 vs. 46 IU/mL in 2011, p < 0.0001).
Conclusion: We report on high rubella seroprevalence among newborns in Serbia, as a proxy of rubella serostatus
of childbearing aged women. Notably, declining trend of rubella antibodies toward diminishing titers suggest the
importance of sustained rubella serosurvey and antenatal screening at the national level.
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Background
Rubella virus (RV) is a single stranded positive sense
RNA virus, of the family Togaviridae, the causative agent
of an acute maculopapular rash disease. Rubella is gener-
ally presenting as mild illness, especially in children.
However, when contracted in early pregnancy (8–10
weeks gestation), the risk of intrauterine transmission is
up to 90 %. Maternal viremia may lead to placental in-
fection and spread of the virus, causing a chronic infec-
tion of the fetus and development of Congenital Rubella
Syndrome (CRS) [1, 2]. First rubella vaccination pro-
grams were introduced in developed countries in the late
1960s and early 1970s, and have influenced greatly the
epidemiology of rubella. A number of countries have re-
ported elimination of indigenous rubella disease. How-
ever, rubella vaccination has been introduced in differing
schedules resulting in marked differences in the rubella
susceptibility profile and rubella epidemiology in differ-
ent countries [3]. The elimination of rubella (<1 case per
million inhabitants) and control of CRS (<1 case per 100
000 live births) have been placed among the public heath
priorities in Europe, with a renewed target set to 2015
[4, 5].
In Serbia, vaccination against rubella was included in
the national vaccination schedule in 1994, as combined* Correspondence: mstanojevic@med.bg.ac.rs
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measles, mumps and rubella vaccine (MMR). Yet, the
vaccine was already available in preceding years, for ap-
plication on individual bases, upon parents’ request,
through both the private and public sector. Until 2006,
MMR vaccination was offered as single dose, for all chil-
dren aged 12–15 month, while since 2006, a second dose of
MMR vaccine is given to pre-school children aged 6. Ac-
cording to the official Serbian Ministry of Health reported
data compiled by WHO and UNICEF, in the initial years of
MMR vaccine introduction in Serbia, 1994 and 1995,
immunization coverage was 81 and 86 %, respectively.
Since, immunization coverage reached over 90 %, with peri-
odic downfalls, such as 1999, 84 % or 2003, 87 %. For the
two study years, 2010/2011, measles and rubella first dose
coverage of 95 and 93 %, respectively, has been reported,
however, more recently a decline below 90 % has been
noted again [6]. Particularities of rubella epidemiology in
Serbia both in pre vaccination era and after introduction of
vaccine are only sporadically documented. Few outbreaks
have been reported such as the one that occurred Belgrade
in 1993, concomitant to measles outbreak, affecting mostly
age groups 5–9 and 0–4 [7]. Although rubella and CRS
reporting have been mandatory even before vaccine intro-
duction epidemiological data are incomplete and discrep-
ant, whereas surveillance data are limited, in many cases
with no laboratory confirmation [8]. However, based on the
WHO data, the number of reported rubella cases in Serbia
in the last decade is gradually declining. Estimated rubella
incidence in Serbia, based on the annual number of re-
ported cases, dropped from 31.3 per 100.000 in 2000 to 0.2
per 100.000 in 2010 [9]. No cases of CRS were reported in
the last decade, however, in view of no active surveillance
for rubella, as qualified by WHO, these data might subject
to under-reporting [10]. Apart from serosurvey data which
reported seroprevalence of >97 % among women of repro-
ductive age in 90’s, no recent data exist about rubella sero-
prevalence in any target population in Serbia [11]. Hence,
in spite of solid MMR uptake, in the view of changing vac-
cination strategies and possible gaps in surveillance it is im-
portant to assess rubella serostatus among target groups
such as pregnant women.
Since it is well known that transplacental transport al-
lows transfer of maternal IgG antibodies to offspring
across the placenta, newborn antibody levels correlate to
maternal antibody status and concentration [12]. This
study was undertaken to assess rubella seroprevalence
and antibody levels in preterm and full-term neonates
treated at the Institute of Neonatology in Belgrade,
Serbia, in 2010–2011, as a proxy for maternal antibody
status and concentration.
Methods
Serological testing for rubella was done within blood
screening for TORCH agents (Toxoplasma gondii,
Rubella virus, Cytomegalovirus, Herpes simplex virus) of
neonates treated at the Institute of Neonatology in
Belgrade, from January 2010 to December 2011. Institute
of Neonatology in Belgrade, Serbia is a specialized ter-
tiary pediatric healthcare hospital, serving as the national
reference center for neonatal care. This institution is
treating around 1000 neonatal patients yearly. All treated
patients are referred from other maternity units all over
the country. Patients were included upon broad clinical
criteria suggesting possible intrauterine infection. Indica-
tions for rubella serology testing were not limited to case
definition of CRS, but included the presence of diverse
inflammatory, metabolic and congenital anomalies, cen-
tral nervous system anomalies, intrauterine growth re-
striction. All eligible neonates were recruited upon
parents’ consent, and blood samples were collected in-
patient, during initial hospitalization upon birth, the
length of which depended on clinical course and out-
come. The outliers were excluded from statistical ana-
lysis. We had no access to the information about
maternal rubella vaccination status. The study was con-
ducted under the approval of the Ethical committee of
the Institute of Neonatology.
Rubella testing was carried out using commercial En-
zyme Linked Immunosorbent Assay (ELISA) tests for
anti-rubella virus IgM and IgG (Anti-Rubella Virus
ELISA, Euroimmun, Luebeck, Germany), according to
manufacturer’s instructions. For the used anti-rubella
virus IgG test the manufacturer reported test specificity
and sensitivity of 100 and 99.6 %, respectively, whereas
reported specificity and sensitivity for the IgM test were
98.6 and 96.4 %. The calibrators used for the qualitative
IgG assay were 10 IU/ml, 50 IU/ml and 200 IU/ml. All
individuals with rubella IgG concentration ≥10 IU/ml
were considered seropositive and those with concentra-
tions below that threshold were considered seronegative
for rubella. Opposite to early seroepidemiological studies
based on classical serological reactions (HI, radial immu-
nodiffusion) that considered 15 IU/ml as the minimum
rubella immune titre [13, 14], we used 10 IU/ml as the
positive/negative cut-off for rubella IgG antibody detec-
tion and evidence of protection, according to more re-
cent epidemiological studies and widespread use of more
sensitive techniques such as ELISA [15, 16]. All samples
that tested positive for anti-rubella virus IgM antibodies
were repeatedly tested using the Enzygnost Anti-Rubella
Virus/IgM (Siemens Healthcare Diagnostics, Marburg,
Germany), as per manufacturer’s instructions.
Obtained results were processed using standard statis-
tical analysis. All analyses were performed using an elec-
tronic database organized in the SPSS (version 11.5)
statistical package Prevalence values were calculated
with a 95 % Wilson score confidence interval based on a
binomial distribution. Categorical data were compared
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using the chi-square test or Fisher’s exact test, while
continuous data were investigated by means of a t-test,
Mann–Whitney U test and ANOVA.
Results
A total of 599 neonates were enrolled during the study
period whereby 405 and 194 were enrolled in 2010 and
2011 respectively. Mean newborn’s gestational age (GA)
was 32.7 ± 3.8 weeks, whereas mean age at which blood
sample was drawn for testing was 18.6 ± 6 days (range
1–148 days). Mean maternal age was 30.2 ± 6 years
(range 15–48 years) (Table 1). The most prevalent indi-
cations for testing, in two thirds of the samples (374/
599), were intrauterine growth restriction (IUGR) and/or
suspicion of central nervous system disorder. No signifi-
cant difference was identified between the two study
groups (2010 vs. 2011) regarding maternal/infant age,
GA, age at sampling or indications for testing.
Serological testing revealed that 540/599 tested neo-
nates were positive for IgG antibodies to rubella, corre-
sponding to the overall seropositivity rate of 90.2 %
(95 % CI: 87.5–92.3 %) (Table 1). Seropositivity rate
among samples from 2010 was 93.6 % (95 % CI: 90.8–
95.6 %), whereas in samples from 2011 it was found to
be 82.9 % (95 % CI: 76.9–87.6 %), the difference yielding
high statistical significance (p < 0.0001). There was no
difference in average maternal age, gestational age or fre-
quency of receiving blood products among the two study
groups. Excluding from the analysis samples of patients
having received blood/blood products did not influence
the prevalence rate. The highest seropositivity rate was
found among newborns of mothers aged over 30 years,
93.6 % (95 % CI: 89.9–96.0 %), while seroprevalence was
the lowest among newborns of mothers younger than
20, 78.3 % (95 % CI: 58.1–90.3 %), with significant
increase of seroprevalence rate with age, p = 0.02 (Fig. 1,
Table 2). There was no significant difference in sero-
prevalence with regards to infant’s gestational age (Fig. 1,
Table 2).
Overall, mean anti-rubella IgG titer was found to be
71 IU/mL (95 % CI: 66.0 to 75.9 IU/ml); significant dif-
ference was found between average IgG titers in the two
study years: 79 IU/mL in 2010 (95 % CI: 72.9 to 85.0 IU/
ml) vs. 46 IU/mL in 2011 (95 % CI, 37.9 to 54.1 IU/ml),
p < 0.0001. Excluding from the analysis samples of pa-
tients having received blood/blood products did not in-
fluence the mean anti-rubella IgG titer. Among
newborns of gestational age (GA) less than 32 weeks,
mean anti-rubella IgG titer was found to be 59.5 IU/mL
(95 % CI, 52.6 to 62.4 IU/ml), this was significantly lower
compared to the average titer in newborns of GA >
32 weeks of 78 IU/mL (95 % CI, 70.9 to 85.0 IU/ml), p <
0.0001.
In five out of 599 samples the first ELISA testing re-
vealed positive finding of anti-rubella virus IgM anti-
bodies, whereupon two samples were confirmed to be
rubella virus IgM positive on confirmatory analysis. Fur-
ther PCR testing of these 2 samples and serological and
clinical follow-up did not confirm CRS diagnosis (data
not shown).
Discussion
Here, we present the first study of the prevalence and
titer of anti-rubella antibodies among preterm and full-
term newborns in Serbia. We report on high rubella
seroprevalence among newborns in Serbia, as a proxy of
rubella seroprevalence among their mothers - women of
reproductive age. Of note, high seroprevalence was
found, albeit with a decline in titer in the study period.
Table 1 Serological findings and general clinical and demographic data according to study year: seropositive = >10 IU/mL; low titer
= 10–15 IU/mL; GA – gestational age in weeks; age sampling – mean age of sampling in days; BP % – percentage of subjects
havinh received blood/blood products; maternal age – mean age of mothers; SD standard deviation, CI confidence interval
Total 2010 2011 p
Serological findings
Seropositive (%) 540/599 (90.2 %) 380/406 (93.6 %) 160/193 (82.9 %) <0.0001
Mean IgG titer (SD) 71 IU/mL (62) 79 IU/mL (62) 46 IU/mL (57) <0.0001
% low titer IgG (95 % CI) 5 (3.5–7) 4.9 (3.2–7.5) 5.2 (2.8–9.2) – a
Clinical and demographic data
Male No (%) 311 (51.4 %) 201 (49.6 %) 104 (53.6 %) –
Female No (%) 294 (48.6 %) 204 (50.4 %) 90 (46.4 %) –
GA (SD) 32.7 (3.8) 32.5 (3.9) 32.9 (3.5) –
Mean age of neonates (SD) 18.6 (22.1) 20.1 (24.3) 16.9 (19.2) –
BP % (95%CI) 34.7 (31.0–38.6) 35.1 (30.6–39.8) 32.6 (26.4–39.5) –
Maternal age in years (range) 30.2 (15–48) 30.1 (16–48) 30.3 (15–45) –
aindicates no statistically significant difference
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Widespread use of rubella vaccine has dramatically re-
duced the disease burden around the globe. In 1996, the
first global survey on the use of rubella vaccines found
that it was administered in 83 countries, including
Serbia [17]. By 2010, when our study was initiated, that
number reached 130. In Europe, 74 % of countries had
introduced rubella vaccination in routine schedule by
1996, whereas by 2010 this was the case in all the coun-
tries of the WHO European region [18]. Nonetheless,
periodical rubella outbreaks are still being reported
worldwide. Despite rubella vaccination being present in
Japan since mid-seventies of the last century, in 2012/
2013, a large rubella outbreak emerged in that country,
in particular in Tokyo region [19]. Nearly a quarter of
these cases, 23 %, were in females. During this outbreak,
since October 2012, 10 CRS cases have been reported in
Japan [19]. Increased risk for CRS has been noted in
some European countries also: in 2013, Poland reported
over 20,000 rubella cases (55.2 per 100,000 inhabitants)
[20]. Recently, rubella outbreaks have also been reported
in some Balkans countries, sharing borders with Serbia.
According to WHO vaccine-preventable diseases
Fig. 1 a Anti-rubella IgG titer in newborns in relation to maternal age. b Anti-rubella IgG titer in newborns in relation to gestational age
Table 2 Rubella seroprevalence and titer in relation to maternal age and gestational age of newborns
Maternal age <20 20 - 30 >30 p
% seropositive (95 % CI) 78.3 (58.1–90.3) 89.3 (85.0–92.4) 93.6 (89.9–96.0) 0.0182a
Mean IgG titer (SD) 60 IU/mL (67) 75 IU/mL (65) 72 IU/mL (62) –b
GA (weeks) <32 >32
% seropositive (95 % CI) 90.1 (86.7–92.8) 90.1 (85.6–93.3) –
Mean IgG titer (SD) 59.5 IU/mL (53) 78 IU/mL (66) p < 0.0001
achi-square test for trend
bindicates no statistically significant difference
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monitoring data, in 2011/2012 an outbreak involving
nearly 25,000 rubella cases was reported in Romania,
with 126 CRS cases reported in the period 2012–2014
[21]. Over 2000 cases were reported in the north-west
Romanian region of Salaj [22]. The incidence of rubella
in Salaj reached 763 cases per 100,000 populations, the
highest one being among high school teenagers, both
girls and boys, aged between 15 and 19 years. Vaccin-
ation coverage among the reported cases was low, 2.1 %
of the total number of cases were vaccinated with at
least one dose of rubella-containing vaccine [22]. In
2009 an outbreak of rubella was reported in Bosnia and
Herzegovina, involving several hundred cases and affect-
ing mainly unvaccinated or partially vaccinated 16–17
year-old school children [23].
In our study we assess rubella seroprevalence among
women of reproductive age through serosurvey among
newborn infants. Placental transfer of maternal IgG anti-
bodies to the fetus is an important mechanism that pro-
vides protection to the infant; hence seroprevalence
among newborn infants reflects the one of their
mothers. In the neonatal population under study we
found an overall seropositivity rate of 90.2 % that reflects
the seroprevalence among women of childbearing age.
Comparison of rubella seroepidemiology in 16 European
countries and Australia in the period 1996–2004 found
an overall seroprevalence ranged from 42.9 to 99.1 %
[24]. However, in the adult population, in particular
among women of childbearing age, rubella seropreva-
lence was similar to the one we found, ranging from
86.6–98.6 %. This study included countries with diverse
vaccine practice and coverage: from no rubella va-
ccination in the schedule at time of analysis to single or
double dose schedule. A recent study in The
Netherlands found an overall nationwide seroprevalence
of 95 %, after more than three decades of high vaccin-
ation coverage [25]. Herd immunity of about 80 % is
considered protective and high vaccine coverage is ex-
pected to account for adequate seroprevalence [16]. Ac-
cording to the official Serbian Ministry of Health
reported data compiled by WHO and UNICEF, for the
two study years, 2010/2011, measles and rubella first
dose coverage of 95 and 93 %, respectively, has been re-
ported, however, more recently a decline below 90 % has
been noted again [6]. Hence, in spite of solid vaccine
coverage, unreached pockets of population have been
identified, such as Roma people from unofficial settle-
ments, largely out of scope of the public health system
[26]. Suboptimal vaccination coverage has been shown
to induce an increase in congenital rubella syndrome oc-
currence, due to a decreased circulation of the virus and
an accumulation of susceptible adult females, as docu-
mented previously in some European countries [27–29].
Several recent reports describe declining rubella
seroprevalence and waning rubella immunity at the
population level, in particular among women of child-
bearing age, in decades following introduction of rubella
vaccination [30, 31]. Our results of significantly lower
seroprevalence and titer may also indicate diminishing
rubella seroprevalence in the second study period, al-
though the analyzed timeframe is narrow, encompassing
only 2 consecutive years. We had no access to the infor-
mation about maternal rubella vaccination status. How-
ever, knowing that rubella vaccine was included into the
national vaccination calendar in 1994, we may hence as-
sume that cohorts of mothers born before 1992 had not
been vaccinated. Since the study period was less than
20 years post rubella vaccine introduction and the average
maternal age in the study was around 30 (range 15–48),
we may conclude that large majority of seropositive in-
fants were born to mothers who acquired immunity after
natural rubella infection, the finding which is supported
by previous studies [32, 33]. This may be due to the differ-
ence in acquiring exposure to RV antigens. Seroepidemio-
logical studies have demonstrated that antibody response
following natural rubella infection is higher and more dur-
able than the one induced by immunization [34]. After ru-
bella vaccination antibody avidity rises in much slower
pace, with high avidity antibodies detected in less than
10 % of vaccinees five months post vaccine administration,
in 20–40 % at 5–9 months, and in 50 % at 10–12 months.
In approximately 30 % of vaccinees, avidity will remain at
moderate levels for many years [16]. Titers of maternal
antibodies to some vaccine preventable diseases have been
shown to be lower and more rapid to decline in children
from vaccinated mothers [35].
Possible limitations to our study refer to the number
of included neonates and the fact that majority of tested
newborns were preterm. Regarding the study size, in
total and in two consecutive years, we found no differ-
ence in average maternal age, gestational age or fre-
quency of receiving blood products among the two
study groups; hence, we believe that these factors might
not fully explain the differences observed. On the other
hand, regarding the impact of preterm delivery to the
obtained serological findings: there is evidence that pla-
cental IgG transfer depends on multiple factors, such as
maternal levels of total and specific IgG antibodies, ges-
tational age, placental integrity, IgG subclass etc. [36].
Most of the antibodies are passed in the third trimester
of pregnancy. Fetal IgG rises from approximately 10 %
of the maternal concentration at 17–22 weeks of gesta-
tion to 50 % at 28–32 weeks of gestation [37]. At term,
fetal IgG typically somewhat exceeds maternal levels.
Nevertheless, although studies of rubella specific anti-
bodies have reported lower antibody titers in preterm
compared to term infants, similar to our findings previ-
ous studies have also shown that majority (50–90 %) of
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preterm infants did possess a protective rubella antibody
titer [38, 39]. In addition, the proportion of subjects with
low level anti-rubella IgG titer (10–15 IU/mL) was simi-
lar in both study periods. Our finding of lower anti-
rubella IgG titer among newborns of GA less than
32 weeks compared to those of GA over 32 weeks is in
accordance to previous reports and in line with expected
dynamics of transplacental antibody transfer [39, 40].
Importantly, follow-up studies have documented that
IgG titers of preterm infants decrease earlier in life
below protective antibody titers than term infants [39].
Consequently, lower titers of transplacentally acquired
IgG in preterm than in term infants, pose preterm in-
fants at higher risk of vaccine preventable diseases early
in life. Our findings of lower anti-rubella seroprevalence
and titer in younger cohorts are concordant to documents
of diminishing herd immunity among women of repro-
ductive age and raise the question of possible widening of
the window of susceptibility to infectious disease in the
first year of life [41]. Ongoing debate on the need to re-
assess vaccination schedule is of particular importance for
premature, but also for infants born at term [42].
Conclusion
In conclusion, we report on high rubella seroprevalence
among newborns in Serbia, as a proxy of rubella sero-
prevalence among childbearing women. Notably, a ten-
dency towards diminishing anti-rubella IgG titer was
found in the study period, implying continued need for
rubella serosurvey and antenatal screening. High im-
munity against rubella, especially in pregnant women, is
prerequisite for achieving the goal set by WHO to elim-
inate endemic rubella and CRS in the European region,
highlighting the importance of seroepidemiological stud-
ies to monitor epidemiological status and vaccination
program at the national level.
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